Support of personalized medicine through risk-stratified treatment recommendations - an environmental scan of clinical practice guidelines
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Background: Risk-stratified treatment recommendations facilitate treatment decision-making that balances patient-specific risks and preferences. It is unclear if and how such recommendations are developed in clinical practice guidelines (CPGs). Our aim was to assess if and how CPGs develop risk-stratified treatment recommendations for the prevention or treatment of common chronic diseases. Methods: We searched the United States National Guideline Clearinghouse for US, Canadian and National Institute for Health and Clinical Excellence (United Kingdom) CPGs for heart disease, stroke, cancer, chronic obstructive pulmonary disease and diabetes that make risk-stratified treatment recommendations. We included only those CPGs that made risk-stratified treatment recommendations based on risk assessment tools. Two reviewers independently identified CPGs and extracted information on recommended risk assessment tools; type of evidence about treatment benefits and harms; methods for linking risk estimates to treatment evidence and for developing treatment thresholds; and consideration of patient preferences. Results: We identified 20 CPGs that made risk-stratified treatment recommendations out of 133 CPGs that made any type of treatment recommendations for the chronic diseases considered in this study. Of the included 20 CPGs, 16 (80%) used evidence about treatment benefits from randomized controlled trials, meta-analyses or other guidelines, and the source of evidence was unclear in the remaining four (20%) CPGs. Nine CPGs (45%) used evidence on harms from randomized controlled trials or observational studies, while 11 CPGs (55%) did not clearly refer to harms. Nine CPGs (45%) explained how risk prediction and evidence about treatments effects were linked (for example, applying estimates of relative risk reductions to absolute risks), but only one CPG (5%) assessed benefit and harm quantitatively and three CPGs (15%) explicitly reported consideration of patient preferences. Conclusions: Only a small proportion of CPGs for chronic diseases make risk-stratified treatment recommendations with a focus on heart disease and stroke prevention, diabetes and breast cancer. For most CPGs it is unclear how risk-stratified treatment recommendations were developed. As a consequence, it is uncertain if CPGs support patients and physicians in finding an acceptable benefit- harm balance that reflects both profile-specific outcome risks and preferences.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Standards of medical care in diabetes—2011
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s011 · Cited by 2,880
GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias)
Guyatt, G. H., Oxman, A. D., Vist, G., Kunz, R., Brozek, J., Alonso-Coello, P., Montori, V., Akl, E. A., Djulbegovic, B., & Falck-Ytter, Y. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.07.017 · Cited by 2,798
Going from evidence to recommendations
Guyatt, G. H., Oxman, A. D., Kunz, R., Falck-Ytter, Y., Vist, G. E., Liberati, A., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39493.646875.ae · Cited by 1,810
Prognosis and prognostic research: validating a prognostic model
Altman, D. G., Vergouwe, Y., Royston, P., & Moons, K. G. M. (2009) · BMJ · doi:10.1136/bmj.b605 · Cited by 1,436
Hill, J. C., Whitehurst, D. G., Lewis, M., Bryan, S., Dunn, K. M., Foster, N. E., Konstantinou, K., Main, C. J., Mason, E., Somerville, S., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60937-9 · Cited by 1,306
External validation is necessary in prediction research:
Bleeker, S. E., Moll, H. A., Steyerberg, E. W., Donders, A. R. T., Derksen-Lubsen, G., Grobbee, D. E., & Moons, K. G. M. (2003) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(03)00207-5 · Cited by 710 · cited 2×
“While much research has been done on how to select and appraise evidence on treatment benefits and harms [43,44] and how to judge the validity of prediction models [37-39], it is less clear how to link risk prediction and treatment evidence, how to select a method for benefitharm assessment to develop treatment thresh…”
BackgroundU.S. Preventive Services Task Force* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-6-200903170-00008 · Cited by 533
Dorresteijn, J. A. N., Visseren, F. L. J., Ridker, P. M., Wassink, A. M. J., Paynter, N. P., Steyerberg, E. W., van der Graaf, Y., & Cook, N. R. (2011) · BMJ · doi:10.1136/bmj.d5888 · Cited by 177 · cited 2×
“There is evidence that using risk-stratified treatments is superior to treatments that are not informed by a risk assessment tool [11-13].”
BackgroundConsumer involvement in systematic reviews of comparative effectiveness research
Kreis, J., Puhan, M. A., Schünemann, H. J., & Dickersin, K. (2013) · Health Expectations · doi:10.1111/j.1369-7625.2011.00722.x · Cited by 88 · cited 1×
“As for patient preferences, little research has been done to find ways to include stakeholders in the process of selecting important outcomes, or a benefit-harm assessment method that provides the information patients need in order to make decisions [46-48].”
BackgroundSelf-citation
Cited by
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.002 · Cited by 3,845
Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1)
Thakker, R. V., Newey, P. J., Walls, G. V., Bilezikian, J., Dralle, H., Ebeling, P. R., Melmed, S., Sakurai, A., Tonelli, F., & Brandi, M. L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1230 · Cited by 1,477
Francis, G. L., Waguespack, S. G., Bauer, A. J., Angelos, P., Benvenga, S., Cerutti, J. M., Dinauer, C. A., Hamilton, J., Hay, I. D., Luster, M., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0460 · Cited by 1,238
The Ariadne principles: how to handle multimorbidity in primary care consultations
Muth, C., van den Akker, M., Blom, J. W., Mallen, C. D., Rochon, J., Schellevis, F. G., Becker, A., Beyer, M., Gensichen, J., Kirchner, H., et al. (2014) · BMC Medicine · doi:10.1186/s12916-014-0223-1 · Cited by 292
Metadata
- Authors
- Yu, T., Vollenweider, D., Varadhan, R., Li, T., Boyd, C., & Puhan, M. A.
- Venue
- BMC Medicine
- Published
- 2013-01-09
- Volume
- 11
- Issue
- 1
- Pages
- 7-7
- ISSN
- 1741-7015 (ISSN-L)
- OpenAlex
- W2167595198
- Cited by
- 36
- References
- 9
- FWCI
- 5.99
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Support of personalized medicine through risk-stratified treatment recommendations - an environmental scan of clinical practice guidelines. https://app.cochat.ai/papers/10.1186/1741-7015-11-7
- The paper
- Yu, T., Vollenweider, D., Varadhan, R., Li, T., Boyd, C., & Puhan, M. A. (2013). Support of personalized medicine through risk-stratified treatment recommendations - an environmental scan of clinical practice guidelines. BMC Medicine. https://doi.org/10.1186/1741-7015-11-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.